文献速递免疫规划慢病防控与筛查卫生政策与健康促进

带状疱疹并发症在老年人群中的医疗费用:美国理赔数据库队列研究

Costs of herpes zoster complications in older adults: A cohort study of US claims database.
PubMed 文献 · Vaccine · 2019-01-23

结果显示约10%的免疫功能正常老年带状疱疹患者发生并发症,平均年增量费用为4716美元,神经并发症最高达18323美元。

要点

  • 约10%的免疫功能正常老年带状疱疹患者发生皮肤、神经或眼部并发症。
  • 并发症患者平均年增量费用为4716美元,神经并发症达18323美元。
  • 大部分增量费用发生在带状疱疹发病后第一个季度内。

核心结论

  • 约10%的免疫功能正常老年带状疱疹患者发生并发症,显著增加经济负担。
  • 接种疫苗可抵消部分带状疱疹负担,包括并发症相关费用。

主要发现

  • 22948例带状疱疹伴并发症患者(60%女性,中位年龄62岁)与213232例无并发症患者(63%女性,中位年龄61岁)进行比较。
  • 并发症患者平均年增量未调整费用为4716美元,眼部并发症为2173美元,神经并发症为18323美元。
  • 多数增量费用发生在带状疱疹发病后第一个季度内。
  • 各并发症类型的增量费用随年龄增长而增加,但≥80岁组除外。

临床怎么用

  • 在老年带状疱疹患者中应关注皮肤、神经和眼部并发症的早期识别与管理。
  • 接种带状疱疹疫苗可能减少并发症相关医疗费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Herpes zoster (HZ) incidence increases with age, and the burden of HZ is expected to grow with aging of populations worldwide. We aim to determine the incremental healthcare resource utilization and associated costs of patients with common HZ-related complications other than postherpetic neuralgia (cutaneous, neurologic and ophthalmic) compared to uncomplicated HZ. METHODS: We conducted a retrospective cohort study of commercial health insurance claims covering about 40 million immunocompetent individuals aged ≥50 years at study entry from all over the US, from 2008 to 2013, with follow-up for one year after HZ onset. All-cause healthcare resource utilization and direct healthcare costs were recorded and calculated from six months before until 12 months after HZ onset. The mean costs for HZ patients with complications were compared to the mean costs for patients with uncomplicated HZ. Multivariable regression analyses estimated mean incremental costs adjusted for demographics, comorbidities, type of complication and time period. RESULTS: Over the five-year study period, 22,948 HZ patients (60% women, median age 62 years) who experienced at least one of the selected complications were compared to 213,232 patients (63% women, median age 61 years) with uncomplicated HZ. Overall, the mean annual incremental unadjusted costs for the patients with HZ-related complications were US$4716, ranging from US$2173 for ophthalmic to US$18,323 for neurologic complications. Most of the incremental costs associated with HZ complications were accrued during the first quarter after HZ onset. For each complication type the incremental costs increased with age up to, but not including the oldest group, aged ≥80 years. CONCLUSIONS: Approximately 10% of immunocompetent older patients with HZ develop complications which considerably increase the economic burden of HZ. Vaccination of older adults will offset some of the burden of HZ, including costs associated with HZ-related complications.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Meyers JL, Candrilli SD, Rausch DA, et al. Costs of herpes zoster complications in older adults: A cohort study of US claims database. Vaccine. 2019. PMID: 30685248. doi:10.1016/j.vaccine.2018.11.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。